A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA

Condition studied

Progressive systemic autoimmune disease resistant to B cell depletion

Investigational medicinal product(s)

Eligibility

Primary endpoint

Incidence of any grade ≥ 3 CRS or grade ≥ 3 ICANS, any grade ≥ 3 organ toxicity that does not resolve to grade ≤ 2 within 72 hours, any grade ≥ 3 immune effector cell-associated hemophagocytosis, grade ≥ 2 ICANS and CRS that does not resolve to grade 1 within 7 days following adequate therapy